SY 005
Alternative Names: Annexin A5 based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals; Dianexin based therapeutics - Lawson Health Research Institute/… See moreLatest Information Update: 28 May 2022
Price :
$50 *
At a glance
- Originator Lawson Health Research Institute; Yabao Pharmaceutical Group
- Class Biological peptides; Calcium binding proteins; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Sepsis in China (IV, Injection)
- 24 May 2021 Yabao Pharmaceuticals plans a phase II trial for Sepsis (In adults, In the elderly) (IV) in July 2021 (NCT04898322)
- 10 Feb 2021 Lawson Health Research Institute, Ontario Ministry of Colleges and Universities and London Health Sciences Foundation plan the phase I AX-COVID trial for Sepsis and severe COVID-19 infections in Canada (IV, Infusion) (NCT04748757), in March 2021